Unlock instant, AI-driven research and patent intelligence for your innovation.

Compound used for treating ischemia reperfusion injuries

A compound and solvate technology, applied in the field of compounds for the treatment of ischemia-reperfusion injury, can solve the problems of high mortality and injury in patients with acute myocardial infarction

Active Publication Date: 2017-12-08
武汉惠康达科技有限公司
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although heart bypass surgery, intervention and thrombolysis have made great progress, the mortality rate of patients with acute myocardial infarction is still relatively high. ischemia reperfusion injury

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compound used for treating ischemia reperfusion injuries
  • Compound used for treating ischemia reperfusion injuries
  • Compound used for treating ischemia reperfusion injuries

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0147] Example 1 The inhibitory effect of ML355 on liver ischemia-reperfusion injury is dose-dependent

[0148] In order to verify the inhibitory effect of different doses of ML355 on liver ischemia-reperfusion injury, C57 mice were randomly divided into 4 groups and injected 1mg / kg ML355 (HY-12341, MCE company), 2mg / kg ML355, 3mg / kg through the tail vein. kg ML355 and solvent (control group, DMSO:Solutol:PEG400:water=5:10:20:65 (v:v:v:v)), and then perform I / R surgery according to the method of the aforementioned liver I / R animal model . At different time points after operation, serum and liver tissue were collected for ALT and AST enzyme activity detection and HE staining.

[0149] The test results of ALT and AST are as follows: Figure 1A , Figure 1B As shown, compared with the solvent control group, after ML355 administration, the ALT and AST contents in the serum of mice were significantly reduced at 6 hours after the operation, and the ALT and AST contents in the ML355 3mg / k...

Embodiment 2

[0151] Example 2 ML355 effectively relieves liver damage caused by ischemia-reperfusion

[0152] In order to study the protective effect of ML355 on liver ischemia-reperfusion at different times, C57 mice were randomly divided into 7 groups, each with 20 mice. Ten mice in each group were given 3 mg / kg of ML355 dissolved in solvent through tail vein injection, and the other ten mice were given solvent. After the administration was completed, 7 groups of mice were subjected to I / R surgery (one group was the Sham control group, and the remaining 6 groups were the I / R experimental group). The Sham control group and the postoperative 0h, 1h, 3h, 6h, 12h, 24h I / R experimental group mouse serum, ALT, AST test to evaluate the degree of liver damage; Sham control group and postoperative 0h, 6h I / R experimental group mouse liver tissues, made paraffin sections, TUNEL Staining, Mac1 immunofluorescence staining and Ly6G immunofluorescence staining to evaluate liver cell apoptosis and liver ...

Embodiment 3

[0157] Example 3 ML355 inhibits ischemia-reperfusion injury in different tissues

[0158] 1. ML355 inhibits cardiac ischemia-reperfusion injury

[0159] C57 mice were randomly divided into 4 groups (Sham group, I / R 6h group, I / R 12h group, I / R 24h group), 7 mice in the Sham group, 15 mice in each of the other 3 groups, of which the I / R group Seven mice were given 3 mg / kg of ML355 dissolved in solvent through tail vein injection, and the other 8 mice and the Sham group were given solvent. After the administration, the 4 groups of mice were subjected to I / R surgery, and the serum of the Sham control group and the I / R experimental group at 6h, 12h, and 24h after the operation were taken for CK and LDH detection to evaluate the degree of cardiac damage.

[0160] The experimental results are as Figure 6A with 6B As shown, the serum levels of CK and LDH increased significantly after I / R. When ML355 was given through the tail vein, the serum CK content was lower than that of the ML355 gr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention provides applications of a compound represented by formula (I), or a pharmaceutically acceptable salt or a solvate, or a metabolin of the compound in preparation of drugs used for treating ischemia reperfusion injuries, and related diseases, inflammatory diseases, and cell death related diseases, wherein the ischemia reperfusion injuries are ischemia reperfusion injuries of liver, heart, kidney, and brain preferable.

Description

Technical field [0001] The present invention belongs to the technical field of medicinal chemistry, and particularly relates to the preparation of compounds of formula (I), or pharmaceutically acceptable salts, or solvates, or metabolites thereof for the treatment of ischemia-reperfusion injury and related diseases, inflammatory diseases, Use in drugs for cell death-related diseases, especially drugs for treating body damage caused by ischemia and reperfusion of organs such as liver, heart, kidney, and brain. Background technique [0002] Ischemia-Reperfusion Injury (IRI) is a concept first proposed by Jennings in 1960. It refers to the blood reperfusion of tissues and organs after ischemia, which not only cannot restore the function of tissues and organs, but aggravates the dysfunction and structure of tissues and organs. damage. Ischemia-reperfusion injury can occur in many important organs, including heart, liver, lung, kidney, gastrointestinal tract and so on. [0003] Hepati...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/63A61K31/635A61P9/10A61P1/16C07D277/44C07D277/82C07D215/36C07D217/02C07D211/26C07D295/135C07D213/76C07D217/22C07D215/40C07C311/44
CPCA61K31/63A61K31/635C07C311/44C07D211/26C07D213/76C07D215/36C07D215/40C07D217/02C07D217/22C07D277/44C07D277/82C07D295/135
Inventor 李红良张晓晶
Owner 武汉惠康达科技有限公司